Recent advances in recombinant DNA technology— especially “CRISPR” techniques—have raised public interest in the potential for GENOME EDITING to change the future of medicine, and potentially, of human society at large.
An essential distinction for understanding evolving issues is the difference between genetic interventions intended to affect only an individual subject versus approaches intended to alter GERM LINE cells in ways that may be passed on to future generations.
This paper provides a brief background in these topics so readers can better understand the roles of Gene Therapy and Genome Editing in clinical trials and pharmaceutical development.
Download this whitepaper to learn more about gene therapy and genomic editing.
Speak With Our Experts